<DOC>
	<DOCNO>NCT00002598</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . Interferon alfa may interfere growth cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy interferon alfa treat patient chronic myelogenous leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Interferon Alfa Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine effectiveness induction high-dose mitoxantrone cytarabine patient chronic myelogenous leukemia ( CML ) blast crisis . - Determine toxicity activity consolidation high-dose cyclophosphamide etoposide patient . - Determine toxicity activity maintenance interferon alfa patient . - Determine efficacy tolerability regimen patient . - Assess minimal residual disease cytogenetics , DNA gene rearrangement ( Southern blot ) , polymerase chain reaction ( PCR ) patient treated regimen , use semiquantitative PCR evaluate antileukemic activity subsequent phase treatment patient achieve complete remission . OUTLINE : Patients stratify prior therapy blast crisis ( yes v ) . - Induction : Patients receive high-dose cytarabine IV 3 hour day 1-5 mitoxantrone IV day 3 . Sargramostim ( GM-CSF ) administer subcutaneously ( SC ) ( IV 4 hour ) daily begin day 7 continue blood count recover . After completion induction , patient suitable HLA-identical bone marrow donor undergo allogeneic bone marrow transplantation accord appropriate IRB-approved protocol . Patients without donor proceed consolidation approximately 4 week hospital discharge follow induction . - Consolidation : Patients receive high-dose cyclophosphamide IV day 1-4 etoposide IV continuously day 5-7 . GM-CSF administer SC ( IV 4 hour ) begin day 8 continue blood count recover . Patients achieve second chronic phase complete remission proceed maintenance approximately 4 week hospital discharge follow consolidation . - Maintenance : Patients receive interferon alfa SC day 1 . Treatment interferon alfa continue daily absence disease progression unacceptable toxicity . Patients CNS involvement entry develop CNS disease study receive CNS therapy outline . - CNS therapy : Patients undergo whole brain irradiation soon possible concurrently mitoxantrone . Patients also receive methotrexate intrathecally 3 time week CSF clear , weekly 4 week , monthly 6 month . PROJECTED ACCRUAL : A total 14-30 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic myelogenous leukemia blast crisis Bone marrow blast least 20 % OR Bone marrow blast plus promyelocytes least 50 % Ineligible high priority protocols PATIENT CHARACTERISTICS : Age : 16 Performance status : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 2.0 mg/dL Renal : Creatinine le 2.0 mg/dL Cardiovascular : LVEF great 50 % MUGA scan echocardiogram Other : HIV negative Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other Prior therapy blast crisis allow</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
</DOC>